1. Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac dysfunction during each year of the observational followup period and the TCZ treatment period.
Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac dysfunction during each year of the observational followup period and the TCZ treatment period. Overall, 5573, 5168, and 4721 patients were observed during the > 0 to 12 months, > 12 to 24 months, and > 24 to 36 months followup periods, respectively, while 5573, 4208, and 3462 patients were followed during the same intervals of TCZ treatment. GI: gastrointestinal; TCZ: tocilizumab.
Kazuhiko Yamamoto et al. J Rheumatol 2015;42:
©2015 by The Journal of Rheumatology